208 related articles for article (PubMed ID: 32673439)
41. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
42. Ten-year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program.
Phan V; Park JA; Dulman R; Lewis A; Briere N; Notarangelo B; Yang E
Eur J Haematol; 2022 Nov; 109(5):465-473. PubMed ID: 35811388
[TBL] [Abstract][Full Text] [Related]
43. Expanding the role of hydroxyurea in children with sickle cell disease.
Rogers ZR; Buchanan GR
J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
[No Abstract] [Full Text] [Related]
44. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
45. Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
Karkoska K; Quinn CT; Niss O; Pfeiffer A; Dong M; Vinks AA; McGann PT
Am J Hematol; 2021 May; 96(5):538-544. PubMed ID: 33534136
[TBL] [Abstract][Full Text] [Related]
46. Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol.
Gwer SO; Onyango KO
JBI Database System Rev Implement Rep; 2018 May; 16(5):1135-1140. PubMed ID: 29762306
[TBL] [Abstract][Full Text] [Related]
47. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Pulte ED; McKenzie SE; Caro J; Ballas SK
Hemoglobin; 2014; 38(6):385-9. PubMed ID: 25405915
[TBL] [Abstract][Full Text] [Related]
48. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
49. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
Nnebe-Agumadu U; Adebayo IA; Nnodu O; Adekile A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28632. PubMed ID: 32743869
[No Abstract] [Full Text] [Related]
50. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.
Charache S; Terrin ML; Moore RD; Dover GJ; McMahon RP; Barton FB; Waclawiw M; Eckert SV
Control Clin Trials; 1995 Dec; 16(6):432-46. PubMed ID: 8925656
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.
Ware RE; Despotovic JM; Mortier NA; Flanagan JM; He J; Smeltzer MP; Kimble AC; Aygun B; Wu S; Howard T; Sparreboom A
Blood; 2011 Nov; 118(18):4985-91. PubMed ID: 21876119
[TBL] [Abstract][Full Text] [Related]
52. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
[TBL] [Abstract][Full Text] [Related]
53. Hydroxyurea in sickle cell disease.
Burke SM
MCN Am J Matern Child Nurs; 1996; 21(4):210. PubMed ID: 8754440
[No Abstract] [Full Text] [Related]
54. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
Thompson BW; Miller ST; Rogers ZR; Rees RC; Ware RE; Waclawiw MA; Iyer RV; Casella JF; Luchtman-Jones L; Rana S; Thornburg CD; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik S; Howard TH; Luck L; Wang WC
Pediatr Blood Cancer; 2010 Feb; 54(2):250-5. PubMed ID: 19731330
[TBL] [Abstract][Full Text] [Related]
55. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
56. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
Saleh AW; Velvis HJ; Gu LH; Hillen HF; Huisman TH
Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
[TBL] [Abstract][Full Text] [Related]
57. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
58. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
[No Abstract] [Full Text] [Related]
59. Minimal doses of hydroxyurea for sickle cell disease.
Lima CS; Arruda VR; Costa FF; Saad ST
Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
[TBL] [Abstract][Full Text] [Related]
60. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
